IMO-3100

IMO-3100 is a synthetic DNA-based antagonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 9 (TLR9), developed for the treatment of autoimmune and inflammatory diseases. It acts by inhibiting TLR7- and TLR9-mediated immune responses, thereby reducing the production of multiple pro-inflammatory cytokines such as IL-6, TNF-alpha, IFN-gamma, IP-10, and others. Unlike therapies that target individual cytokines, IMO-3100 blocks upstream signaling pathways involved in inflammation. Preclinical studies have demonstrated its efficacy in models of lupus, rheumatoid arthritis, psoriasis, hyperlipidemia, and other immune-mediated conditions. The drug was originally developed by Idera Pharmaceuticals (now Aceragen) and has reached Phase 2 clinical development for indications including plaque psoriasis[1][2][3][4][5][6].